Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
22 07 2021
Historique:
received: 28 01 2021
revised: 11 04 2021
accepted: 15 04 2021
pubmed: 2 6 2021
medline: 28 9 2021
entrez: 1 6 2021
Statut: ppublish

Résumé

Bone fragility is increasingly recognized as a relevant complication of type 2 diabetes (T2D) and diabetic patients with fragility fractures have higher mortality rates than non diabetic individuals or diabetic patients without fractures. However, current diagnostic approaches for fracture risk stratification, such as bone mineral density measurement or the use of risk assessment algorithms, largely underestimate fracture risk in T2D patients. A multidisciplinary expert panel was established in order to in order to formulate clinical consensus recommendations on bone health assessment and management of fracture risk in patients with T2D. The following key questions were addressed: a) which are the risk factors for bone fragility in T2D?, b) which diagnostic procedures can be currently used to stratify fracture risk in T2D patients?, c) which are the effects of antidiabetic treatments on bone?, and d) how to prevent and treat bone fragility in T2D patients? Based on the available data members of this panel suggest that the stratification of fracture risk in patients with diabetes should firstly rely on the presence of a previous fragility fracture and on the individual risk profile, with the inclusion of T2D-specific risk factors (namely T2D duration above 10 yrs, presence of chronic T2D complications, use of insulin or thiazolidinediones and persistent HbA1c levels above 8% for at least 1 year). Two independent diagnostic approaches were then suggested in the presence or the absence of a prevalent fragility fracture, respectively. Clinical trials in T2D patients at risk for fragility fractures are needed to determine the efficacy and safety of available antiresorptive and anabolic agents in this specific setting.

Identifiants

pubmed: 34059385
pii: S0939-4753(21)00184-8
doi: 10.1016/j.numecd.2021.04.014
pii:
doi:

Substances chimiques

Bone Density Conservation Agents 0
Hypoglycemic Agents 0

Types de publication

Journal Article Practice Guideline Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2210-2233

Informations de copyright

Copyright © 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Auteurs

Iacopo Chiodini (I)

Unit for Bone Metabolism Diseases and Diabetes and Lab of Endocrine and Metabolic Research, IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Medical Science and Community Health, University of Milan, Milan, Italy.

Agostino Gaudio (A)

Department of Clinical and Experimental Medicine, University of Catania, University Hospital "G. Rodolico" Catania, Italy.

Andrea Palermo (A)

Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy.

Nicola Napoli (N)

Department of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy.

Fabio Vescini (F)

Endocrinology and Metabolism Unit, University-Hospital S. M. Misericordia of Udine, Italy.

Alberto Falchetti (A)

Unit for Bone Metabolism Diseases and Diabetes and Lab of Endocrine and Metabolic Research, IRCCS Istituto Auxologico Italiano, Milan, Italy; EndOsMet, Villa Donatello Private Hospital, Florence, Italy.

Daniela Merlotti (D)

Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy; Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Cristina Eller-Vainicher (C)

Endocrinology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Vincenzo Carnevale (V)

Unit of Internal Medicine, "Casa Sollievo della Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, (FG), Italy.

Alfredo Scillitani (A)

Unit of Endocrinology, "Casa Sollievo della Sofferenza" Hospital, IRCCS, San Giovanni Rotondo, (FG), Italy.

Giuseppe Pugliese (G)

Department of Clinical and Molecular Medicine, "La Sapienza" University, and Diabetes Unit, Sant'Andrea University Hospital, Rome, Italy.

Domenico Rendina (D)

Department of Clinical Medicine and Surgery, "Federico II" University of Naples, Naples, Italy.

Antonio Salcuni (A)

Endocrinology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Francesco Bertoldo (F)

Department of Medicine, University of Verona, Policlinico GB Rossi, Verona, Italy.

Stefano Gonnelli (S)

Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy.

Ranuccio Nuti (R)

Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy.

Vincenzo Toscano (V)

Department of Clinical and Molecular Medicine, "La Sapienza" University, Rome, Italy.

Vincenzo Triggiani (V)

Interdisciplinary Department of Medicine, Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari "Aldo Moro", Bari, Italy.

Simone Cenci (S)

Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy.

Luigi Gennari (L)

Department of Medicine, Surgery and Neurosciences, University of Siena, Policlinico Le Scotte, Siena, Italy. Electronic address: luigi.gennari@unisi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH